ABSTRACT
48

INTRODUCTION
49
Preeclampsia is a serious pregnancy disorder characterized by hypertension and 50 proteinuria, which affects between 3-5% of pregnancies worldwide (21). Besides being a major 51 cause of maternal and perinatal mortality and morbidity (16, 24) , preeclamptic women and their 52 offspring are at increased risk for developing cardiovascular diseases later in life (13, 35) . In 
67
Indeed, circulating leptin levels are greater in pregnant women than their non-pregnant 68 counterparts. However, hyperleptinemia over the levels seen in normal pregnancy has been 69 associated with preeclampsia (19, 47) . This is important because leptin has been shown to have 70 direct effects on blood pressure regulation in male rats (51). Clinical studies have also shown 71 that increased circulating leptin levels are associated with increased risk for the development of 72 preeclampsia (43, 50) , and the degree of hyperleptinemia in preeclamptic women is correlated 4 with disease severity (1). Therefore, because hyperleptinemia is consistently observed in obese 74 humans and animal models (58), this is a potential mechanism that links obesity with the 75 development of hypertension in preeclampsia.
76
Growing evidence supports that incomplete remodeling of uterine spiral arteries results
77
in reduced placental perfusion. The hypoxic/ischemic placenta, in turn, releases multiple 
82
leptin with sFlt-1 (15) or TNF-α (7) in preeclampsia. However, the direct effect of 83 hyperleptinemia on these placental factors and blood pressure regulation during pregnancy are 84 unknown. Therefore, the purpose of the present study was to test the hypothesis that chronic 85 exposure to hyperleptinemia increases blood pressure and placental sFlt-1 and TNF-α levels in 86 pregnant rats.
88
METHODS
89
Animals. All protocols were approved by the University of Mississippi Medical Center
90
Institutional Animal Care and Use Committee, and followed the National Institutes of Health
91
Guide for the Care and Use of Laboratory Animals. Age-matched, timed-pregnant Sprague
92
Dawley rats (Harlan, Indianapolis, IN) were received on gestational day (GD) 11. They were 93 maintained on a 12:12 h light:dark cycle at 23 ºC. On GD 14, rats were randomly assigned to 94 the normal pregnant group with food intake ad libitum (pregnant, n=8-12) , leptin-treated 95 pregnant group with food intake ad libitum (pregnant+LEP, , or normal pregnant group 96 with food intake adjusted to the food intake of pregnant+LEP rats n=11 
107
Blood pressure measurement in conscious rats. On GD 18, rats were anesthetized 108 with isoflurane as described above and implanted with indwelling carotid catheters consisting of 109 V-1 tubing attached to V-3 tubing (Scientific Commodities Inc., Lake Havasu City, AZ).
110
Catheters were tunneled under the skin and externalized at the scapular region. 
135
and supernatants were used to quantify sFlt-1 and TNF-α by ELISA (both from R&D Systems).
136
Total protein concentration in samples was measured using the bicinchoninic acid (BCA) 137 method (Thermo Scientific, Rockford, IL).
138
Statistical analysis. Graphs and statistical analysis were prepared using GraphPad 
162
Maternal body weight and food intake. Initial BW at GD 14 was similar among rats 163 designated for the pregnant group (257.0 ± 4.7 g), the pregnant-FR group (264.4 ± 2.1 g), and 164 the pregnant+LEP group (263.4 ± 2.9 g) ( Figure 4A ; P>0.05). Baseline FI and WI were 165 assessed from GD 13 to 14, and no differences in FI (15.8 ± 1.5 vs. 17.3 ± 0.5 vs. 17.0 ± 1.0 166 g/day; Figure 1B ; P>0.05) or WI (38.0 ± 4.6 vs. 37.3 ± 4.7 vs. 36.1 ± 3.0 mL/day; P>0.05) were 167 found among pregnant, pregnant-FR, and pregnant+LEP groups, respectively.
168
By the end of the study, at GD 18, BW in pregnant-FR and pregnant+LEP rats (280.1 ± 169 2.6 and 284.1 ± 3.9 g, respectively) were decreased compared to pregnant rats (310.3 ± 6.6 g) 8 ( Figure 4A ; P<0.01). From GD 16 to 18, pregnant+LEP rats had lower FI than pregnant rats (GD 171 16: 6.8 ± 0.8 vs. 21.5 ± 0.4 g/day, GD 17: 9.3 ± 1.1 vs. 23.8 ± 0.7 g/day, and GD 18: 11.3 ± 1.2 172 vs. 25.2 ± 1.1 g/day; Figure 4B ; all P<0.0001). Since the mean GD 16-18 FI of pregnant+LEP 173 rat was 8.6 ± 0.8 g/day, we fed pregnant-FR rat 9.0 g/day of chow from GD 14 to 19. WI was 174 lower in pregnant-FR and pregnant+LEP dams than pregnant dams on GD 16-18 (GD 16: 37.8 175 ± 2.0 vs. 23.5 ± 0.9 vs. 49.9 ± 1.7 mL/day, GD 17: 37.5 ± 2.9 vs. 29.5 ± 1.9 vs. 58.9 ± 2.2 176 mL/day, and GD 18 (33.7 ± 2.3 vs. 38.3 ± 2.6 vs. 60.0 ± 2.1 mL/day; all P<0.0001), respectively.
177
Maternal circulating metabolic factors. As shown in Table 1 
184
plasma free fatty acid was reduced in pregnant+LEP rats compared with pregnant rats (P<0.01),
185
but these levels were similar to the free fatty acid level observed in the pregnant-FR group.
187
DISCUSSION
188
The main finding reported here is that chronic hyperleptinemia increases mean arterial 189 pressure in pregnant rats. This alteration during chronic leptin excess was associated with 190 increased placental TNF-α. In parallel to decreases in food intake and body weight, circulating 191 cholesterol, triglyceride, and free fatty acid levels were reduced in leptin-treated pregnant rats.
192
These data suggest that the hyperleptinemia encountered in obesity is itself, in the absence of 
197
concentrations compared to normal pregnant women (1, 6, 18, 20, 36, 38, 40, 41, 47) .
198
Importantly, some reports have suggested that serum leptin can be used as a predictive marker 199 for this syndrome. Hyperleptinemia appears to develop in preeclamptic women during first and 200 second trimester (5, 11, 36, 43, 46, 50) , i.e. before the manifestation of the clinical symptoms. 
284
Perspectives
285
In this study, we tested the hypothesis that chronic hyperleptinemia increases blood 286 pressure and placental factors in pregnant rats. Our results show that sustained hyperleptinemia 287 does raise blood pressure and increase placental TNF-α. Understanding the molecular 288 pathways that regulate the actions of leptin in the cardiovascular system during pregnancy may 289 offer novel pharmacological agents for the treatment of preeclampsia.
290
Obesity is a major risk factor for the onset of preeclampsia. Recent epidemiological data 291 suggest that the rate of preeclampsia has increased largely due to a significant increase in the 
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Augmentation of leptin and hypoxia-inducible factor 1alpha mRNAs in the pre-eclamptic 
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